Serum LACC1 level is a predictor of response to upadacitinib treatment in patients with rheumatoid arthritis: a prospective observational cohort study
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Higher serum LACC1 levels predict a better response to upadacitinib (UPA) treatment in rheumatoid arthritis (RA) patients. This finding may help personalize RA treatment strategies for improved outcomes.
Area Of Science
- Rheumatology
- Immunology
- Pharmacology
Background
- Rheumatoid arthritis (RA) is a chronic autoimmune disease.
- Upadacitinib (UPA) is a Janus kinase (JAK) inhibitor used for RA treatment.
- Predicting treatment response in RA is crucial for effective management.
Purpose Of The Study
- To investigate the predictive role of LACC1 in upadacitinib (UPA) response in rheumatoid arthritis (RA).
- To identify factors associated with treatment response to UPA in RA patients.
Main Methods
- Sixty adult RA patients with inadequate response or intolerance to methotrexate were included.
- Patients received UPA monotherapy (15 mg/day) for 24 weeks.
- Treatment response was evaluated using disease activity indices, joint counts, and patient-reported outcomes.
Main Results
- Higher serum LACC1 levels were associated with a good response to UPA.
- Factors like prolonged disease duration, increased tender joint count, low neutrophil count, and high GM-CSF levels predicted a poor response.
- Age, csDMARD use, and inflammatory markers also correlated with non-response.
Conclusions
- Elevated serum LACC1 levels indicate better efficacy of UPA in RA patients.
- These findings support the potential for individualized dosing strategies based on LACC1 levels.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.